Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism.
Wilkinson DJ, Hossain T, Hill DS, Phillips BE, Crossland H, Williams J, Loughna P, Churchward-Venne TA, Breen L, Phillips SM, Etheridge T, Rathmacher JA, Smith K, Szewczyk NJ, Atherton PJ. · 2013
Read Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism. by Wilkinson DJ, Hossain T, Hill DS, Phillips BE, Crossland H, Williams J, Loughna P, Churchward-Venne TA, Breen L, Phillips SM, Etheridge T, Rathmacher JA, Smith K, Szewczyk NJ, Atherton PJ. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3690694.txt.
Introduction
Wilkinson and colleagues measured how leucine and its breakdown product HMB affect protein metabolism in human skeletal muscle. Leucine, an amino acid from food protein, is the strongest dietary trigger for building new muscle protein. The team asked whether HMB shares or extends that effect. They used tracer methods in volunteers.
Both compounds quickly reached the blood and muscle and both stimulated protein synthesis, leucine more strongly. HMB also cut muscle protein breakdown by more than half, an effect that did not depend on insulin. The authors read this as HMB driving muscle anabolism through partly different routes from leucine, combining a modest synthesis boost with a clear anti-breakdown action.
Catalog record
| CREATOR | Wilkinson DJ, Hossain T, Hill DS, Phillips BE, Crossland H, Williams J, Loughna P, Churchward-Venne TA, Breen L, Phillips SM, Etheridge T, Rathmacher JA, Smith K, Szewczyk NJ, Atherton PJ. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism By D J Wilkinson, T Hossain, D S Hill, B E Phillips, H Crossland, J Williams, P Loughna, T A Churchward-Venne, L Breen, S M Phillips, T Etheridge, J A Rathmacher Published in: The Journal of Physiology DOI: 10.1113/jphysiol.2013.253203 ABSTRACT Maintenance of skeletal muscle mass is contingent upon the dynamic equilibrium (fasted losses–fed gains) in protein turnover. Of all nutrients, the single amino acid leucine (Leu) possesses the most marked anabolic characteristics in acting as a trigger element for the initiation of protein synthesis. While the mechanisms by which Leu is ‘sensed’ have been the subject of great scrutiny, as a branched-chain amino acid, Leu can be catabolized within muscle, thus posing the possibility that metabolites of Leu could be involved in mediating the anabolic effect(s) of Leu. Our objective was to measure muscle protein anabolism in response to Leu and its metabolite HMB. Using [1,2-13C2]Leu and [2H5]phenylalanine tracers, and GC-MS/GC-C-IRMS we studied the effect of HMB or Leu alone on MPS (by tracer incorporation into myofibrils), and for HMB we also measured muscle proteolysis (by arteriovenous (A–V) dilution). Orally consumed 3.42 g free-acid (FA-HMB) HMB (providing 2.42 g of pure HMB) exhibited rapid bioavailability in plasma and muscle and, similarly to 3.42 g Leu, stimulated muscle protein synthesis (MPS; HMB +70%vs. Leu +110%). While HMB and Leu both increased anabolic signalling (mechanistic target of rapamycin; mTOR), this was more pronounced with Leu (i.e. p70S6K1 signalling ≤90 min vs. ≤30 min for HMB). HMB consumption also attenuated muscle protein breakdown (MPB; −57%) in an insulin-independent manner. We conclude that exogenous HMB induces acute muscle anabolism (increased MPS and reduced MPB) albeit perhaps via distinct, and/or additional mechanism(s) to Leu. INTRODUCTION Postabsorptive periods are dominated by negative protein balance (muscle protein breakdown (MPB) exceeds muscle protein synthesis (MPS)) that can only be reversed by food intake. This ‘anabolic’ shift towards a positive protein balance is principally driven via a brief (∼2 h) but substantial (∼3-fold) postprandial elevation in MPS (Atherton et al. 2010a), with a small (∼50%) contribution from MPB depression (Wilkes et al. 2009). Consequently, it follows that adequate nutritional intake is crucial for maintenance of skeletal muscle mass. Much work has been undertaken, over several years, in identifying anabolically active nutrients for skeletal muscle. Early experiments using stable isotope tracer techniques in humans showed that feeding a mixed macronutrient meal approximately doubled rates of MPS (Rennie et al. 1982). Subsequent studies infusing only amino acid (AA) mixtures confirmed the crucial role of essential AAs (EAAs) as the principal drivers of nutritionally stimulated MPS (Bennet et al. 1989). These studies were further refined where robust stimulation of MPS was observed with intravenous flooding doses of the single EAAs phenylalanine, valine and leucine (Leu; Smith et al. 1992, 1998). Since then a plethora of data, from both pre-clinical studies (Anthony et al. 2001; Suryawan et al. 2008) and human studies (Churchward-Venne et al. 2012) have established Leu as one of the most potent EAAs in terms of stimulating MPS. Indeed, in pre-clinical models, Leu is often used as a paradigm for stimulating muscle protein synthesis within the field of skeletal muscle protein metabolic research (Anthony et al. 2000a,b, 2001; Norton et al. 2012). Further underlining the integral role of Leu are studies showing that, of all the EAAs, Leu initiates the greatest ‘anabolic’ signalling responses – ostensibly through the mTORc1–p70S6K1 pathway (Atherton et al. 2010b). It is on this basis that Leu has been suggested as a direct modulator of MPS, in addition to the more obvious role as a substrate. As a branched-chain amino acid (BCAA), Leu is transaminated in muscle by branched-chain aminotransferase (BCAT) to α-ketoisocaproate (α-KIC) before decarboxylation to isovaleryl-CoA by the mitochondrial enzyme branched-chain α-ketoacid dehydrogenase (BCKDH), then finally forming Acyl-CoA derivatives and entering the citric acid cycle. However, in the liver, an alternative metabolic fate for Leu has been shown wherein the cytosolic enzyme α-KIC dioxygenase (or 4-hydroxyphenylpyruvate dioxygenase (HPD); Van Koevering & Nissen, 1992) generates β-hydroxy-β-methylbutyrate (HMB) from Leu. This enzyme has been shown to be expressed in skeletal muscle, in addition to liver and kidney (Fig. 1), this leaves open the question as to whether metabolites of Leu could have direct anabolic effects within muscle. Although it has been scantily investigated and often trialled under poorly controlled experimental conditions for defining the effector (for example, providing Leu metabolites with other AAs), metabolites of Leu, HMB in particular, have been shown to enhance gains in muscle mass and strength. For example, on supplementation with 3 g of HMB during intense resistance exercise training (RET) for 3 weeks, healthy, untrained young men have shown a tendency to increase lean body mass (LBM) and increase strength when compared to a placebo-treated group (Nissen et al. 1996). Furthermore, a study in which elderly women received a supplement containing 2 g HMB plus 1.5 g of lysine and 5 g of arginine for 12 weeks revealed significantly greater strength gains and a trend for increased LBM in the supplemented group (Flakoll et al. 2004). [Figure: Gene expression of HPD Upper panel, mouse tissues; lower panel, human skeletal muscle, with standard RT-PCR temperature gradient program shown for lower panel.] Indications from rodent and cell culture models are that HMB stimulates MPS in a similar fashion to Leu, that is through the mTOR–p70S6K1 pathway (Eley et al. 2007). Intriguingly, HMB can rescue depressions of MPS under both catabolic (e.g. elevated lipopolysaccharide (LPS), cytokines) and also under normal conditions through attenuating depressions in activity of the mTORc1 pathway (Eley et al. 2007). Moreover, HMB has also been shown to attenuate catabolism, reducing MPB via suppression of the ubiquitin-proteasome system (Eley et al. 2008), and by inhibition of myonuclear apoptosis by antagonizing mitochondrial-associated caspases (Hao et al. 2011). Some of these data have translated to human models of muscle catabolism such as: AIDS (Clark et al. 2000), cancer (May et al. 2002) and COPD (Hsieh et al. 2006). Collectively, these data support the notion that HMB could mediate its anabolic or anti-catabolic effects through acutely modulating muscle protein turnover. To date, no study has investigated the possibility that HMB could represent an anabolic metabolite of Leu (responsible for acute effects on protein turnover). In this study we aimed to remedy that by studying the effects of HMB on human muscle protein turnover and compare this with Leu. Our hypotheses were: (i) HMB provision would acutely stimulate MPS (ii) HMB would stimulate MPS through mechanisms similar to its precursor, Leu, and (iii) HMB would also acutely depress MPB. METHODS Ethical approval Ethical approval was obtained from the University of Nottingham Medical School Ethics Committee and the Hamilton Health Sciences Research Ethics Board at McMaster University, with all studies being carried out in accordance with the Declaration of Helsinki. All volunteers were health-screened prior to participation, before providing written informed consent. Subject characteristics and study design Healthy young men (HMB study group: n= 8, mean age 22 ± 1 years, mean body mass index (BMI) 23 ± 1 kg m−2; Leu study group: n= 7, mean age 21 ± 0.3 years, BMI 25 ± 0.6 kg m−2), who were recreationally active but